Clinical Trial

GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,
Trial Details
NCT Number NCT07642700
Lead Sponsor Guoxia Yang
Conditions Chronic Endometritis
Enrollment 150 participants
Start Date 2026-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-11